SCC, BCC Immunotherapy

San Francisco - Topical immunomodulators, specifically imiquimod 5 percent cream (Aldara), may be a viable option for treating patients with invasive squamous cell carcinoma (SCC) or aggressive basal cell carcinoma (BCC) who are no longer candidates for surgery, said Ulrich Hengge, M.D.

Related Videos
Related Content

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.